As I understanding is that Maria has NOT yet satisfied the...

As I understanding is that Maria has NOT yet satisfied the vesting conditions for any of the 3c (pseudo) options. ATM she controls ZIP of it.

* The low bar for the first tranche may be the China distribution deal. That news should propel the SP a cent or so IMHO.

* The medium bar (2nd tranche) is $4m revenue p.a. I say medium but it is higher than what we have ATM. I hope this one does turn out to be a low bar on the basis of OTC sales, royalties and milestone payments.

* The high bar for the third tranche is to get the clinical trial up and going. IND studies including multi species tests are need to be completed first and if successful, the production of sufficient mAB to run the trial will be needed. There are many milestones to be completed prior to the recruitment of patients.



cheers